Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi and Regeneron report positive atopic dermatitis drug trial data

Sanofi and Regeneron report positive atopic dermatitis drug trial data

1st April 2016

Sanofi and Regeneron Pharmaceuticals have announced data from two phase III clinical trials demonstrating the efficacy of their new atopic dermatitis therapy dupilumab.

The LIBERTY AD SOLO 1 and SOLO 2 studies assessed dupilumab as a treatment for adult patients with inadequately controlled moderate to severe atopic dermatitis, and were able to meet their primary endpoints.

It was shown that the drug was able to significantly improve measures of overall disease severity, skin clearing, itching, quality of life and mental health, making it the first systemic therapy to deliver positive phase III trial results in this indication.

Dupilumab has been granted breakthrough therapy designation by US regulators, though it is yet to be fully evaluated by any regulatory authority.

Dr Elias Zerhouni, president of global research and development at Sanofi, said: "These results may bring new hope to atopic dermatitis patients, many of whom have suffered for years."

This comes after Sanofi and Regeneron recently reported clinical data showing the benefits their drug Praluent delivers for heterozygous familial hypercholesterolaemia patients.ADNFCR-8000103-ID-801815780-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.